1:32 PM ยท 21 June 2024

Sarepta Therapeutics gains 37% in pre-market after FDA approval ๐Ÿ“ƒ

Sarepta Therapeutics' soared by 36% in the pre-market trading following the FDA's decision to grant accelerated approval for its gene therapy, Elevidys, extending its use to include non-ambulatory patients with Duchenne muscular dystrophy (DMD). Additionally, the FDA granted traditional approval for Elevidys to treat ambulatory DMD patients who are at least four years old. This broader approval aims to increase access to Elevidys, which costs around $3.2 million per patient, positioning it as one of the most expensive drugs globally. Sarepta has commenced the ENVISION study, a phase 3 trial, to confirm Elevidys' benefits in non-ambulatory and older ambulatory patients, a requirement for maintaining its FDA approval for these groups.

The FDA's decision marks a significant expansion in the treatment of DMD, a serious muscle-weakening disease that mainly affects men in their 20s. Yesterday's FDA approval offers a potential opportunity to significantly increase the company's revenues. Sarepta's strategy includes partnering with Roche Holdings for global commercialization, excluding the US, where Sarepta will remain fully responsible for commercialization.

Source: xStation 5

10 September 2026, 3:49 PM

Stock of the Week: Broadcom: Short-Term Disappointment, Long-Term Growth Story

10 September 2026, 3:18 PM

US OPEN: Bonds keep climbing, semiconductors give back gains

9 September 2026, 6:20 PM

Technical analysis ๐Ÿ“‰ Alphabet shares fall 2% and test the 200-day moving average

9 September 2026, 3:02 PM

US Open: Wall Street sentiments mixed as oil jumps above $100 ๐Ÿ—ฝ Casey General shares tumble 18%

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissรฃo de Valores Mobiliรกrios (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits